Evoke Pharma, Inc. announced a summary of real-world data on the positive impact of GIMOTI (nasal metoclopramide) usage in reducing healthcare costs for patients suffering from diabetic gastroparesis (DGP) versus patients taking oral metoclopramide. The full abstract entitled ?Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs for Treating Diabetic Gastroparesis Patients,? was selected and presented as for a plenary session at the American College of Gastroenterology (ACG) 2023 Annual Meeting in Vancouver, Canada.

Among many conclusions, over the 6-month post index period, Gimoti patients/payers spent approximately $15,000 less than oral metoclopramide patients/payers between medical facility and pharmacy visits.